StudienübersichtFrank2021-05-27T12:15:46+02:00

Studienübersicht

Aktuelle Angebote.

Glioblastom (GBM)

Kurztitel	Beschreibung	Studiendesign	Tumor	Status
N2M2	Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation: NCT Neuro Master Match – N²M² (NOA-18)	Phase I/II	GBM (MGMT unmethylated)	recruiting
–	A Study of LY3200882 in Participants With Solid Tumors	Phase I	Solid Tumors, recurrent GBM	follow-up
TIGER	Studie zur Anwendung von TTFields in der klinischen Routine, bei Patientinnen und Patienten mit einem neudiagnostizierten Glioblastom (GBM) in Deutschland	non-interventionell	GBM	follow-up
EORTC 1419	Molekulare und klinische Faktoren des Langzeitüberlebens bei Glioblastomen	non-interventionell	GBM	recruiting
AMPLIFY-NEOVAC	AMPLIFYing NEOepitope-specific VACcine Responses in progressive diffuse glioma – a randomized, open label, 3 arm multicenter Phase I trial to assess safety, tolerability and immunogenicity of IDH1R132H-specific peptide vaccine in combination with checkpoint inhibitor Avelumab (AMPLIFY-NEOVAC)	Phase I	recurrent Glioma Grade II-IV (Astrocytoma, Oligodendroglioma, GBM)	recruiting
PriCoTTF	PriCoTTF Trial: A phase I/II trial of TTFields prior and concomitant to radiotherapy in newly diagnosed glioblastoma	Phase I/II	GBM	recruiting
SNOXA12C401 (GLORIA)	Single-arm, dose-escalation, Phase 1/2 study of olaptesed pegol (NOX-A12) in combination with irradiation in inoperable or partially resected first-line glioblastoma patients with unmethylated MGMT promoter	Phase I/II	GBM (MGMT unmethylated)	recruiting

Astrozytome / Oligodendrogliome WHO II-III

Kurztitel	Beschreibung	Studiendesign	Tumor	Status
OT-15-001 (STELLAR)	A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy	Phase III	recurrent Anaplastic Astrocytoma	recruiting
GliProPh	Randomisierte Studie zum Vergleich einer Protonen- vs. Photonen- Strahlentherapie für Patienten mit WHO Grad II-III Gliomen (GliProPh)	randomisiert, Berufsordnung	Glioma Grade II-III (Astrocytoma, Oligodendroglioma)	recruiting
–	A Study of LY3200882 in Participants With Solid Tumors	Phase I	Solid Tumors, recurrent GBM	follow-up
AG881-C-004	A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects	Phase III	Residual or recurrent Grade II Glioma	recruiting
	With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation

Melanom

Kurztitel	Beschreibung	Studiendesign	Tumor	Status
–	Neuroimmunologische Nebenwirkung von Checkpoint-Inhibitoren	non-interventionell	Melanoma	recruiting